Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28147499 | 0.83 | ADRA2C (0.51) | ADRA2CMAOBCLK4CHEK1GABRG2 | |
| SCHEMBL7334857 | 0.83 | CYP11B1 (0.46) | ADRA2CMAOBXDHSLC22A12PGR | |
| SCHEMBL996127 | 0.82 | ADRA2C (0.64) | ADRA2CMAOBCLK4CHEK1GABRG2 | |
| SCHEMBL2744983 | 0.81 | XDH (0.47) | MAOBPDK2PTPN5XDHSLC22A12 | |
| SCHEMBL3068700 | 0.80 | SLC22A12 (0.49) | ADRA2CMAOBCLK4GABRG2GABRB3 | |
| SCHEMBL31272452 | 0.78 | ADRA2C (0.60) | ADRA2CMAOBCLK4CHEK1GABRG2 | |
| SCHEMBL3422474 | 0.78 | ADRA2C (0.60) | ADRA2CMAOBCLK4CHEK1GABRG2 | |
| SCHEMBL7391551 | 0.78 | PTGDR2 (0.49) | GABRG2GABRB3GABRA5GABRA3PDCD1 | |
| SCHEMBL5598955 | 0.78 | PTGDR2 (0.46) | CHEK1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL5711323 | 0.78 | LMNA (0.57) | XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2159216-B1 | 3-BUTENYL-1-AMINE DERIVATIVES AND THEIR USE AS Ih MODULORS FOR THE TREATMENT OF PSYCHIATIRC DISORDERS | ORGANON NV (NL) | 2011-10-12 | — | — | EP | disclosed |
| EP-2159216-A1 | Ih - Modulators | N.V. Organon (NL) | 2010-03-03 | — | — | EP | disclosed |
| US-20040229910-A1 | Therapeutic compounds | N.V. ORGANON (NL) | 2004-11-18 | — | — | US | disclosed |
| EP-0779277-B1 | 1,4-DIHYDROPYRIDINE DERIVATIVE | MERCIAN CORP (JP) | 2002-07-10 | — | — | EP | disclosed |
| US-20020037885-A1 | Therapeutic compounds | DIJCKS FREDERICUS ANTONIUS (NL) | 2002-03-28 | — | — | US | disclosed |
| US-6313139-B1 | ADMINISTERING BENZYLAMINE DERIVATIVE FOR THERAPY OF PSYCHIATRIC DISORDER IN MAMMALS | AKZO NOBEL N. V. (NL) | 2001-11-06 | — | — | US | disclosed |
| CN-1275909-A | In-modulators | AKZO NOBEL NV (NL) | 2000-12-06 | — | — | CN | disclosed |
| EP-1035843-A2 | I h?-MODULATORS | Akzo Nobel N.V. (NL) | 2000-09-20 | — | — | EP | disclosed |
| US-6080773-A | USEFUL FOR TREATMENT OF DEPRESSION, ANXIETY OR PSYCHOSIS | AKZO NOBEL, N.V. (NL) | 2000-06-27 | — | — | US | disclosed |
| WO-1999018941-A2 | Ih-MODULATORS | AKZO NOBEL N.V. (NL) | 1999-04-22 | — | — | WO | disclosed |
| US-5760238-A | ANTIISCHEMIC AGENTS | MERCIAN CORPORATION (JP) | 1998-06-02 | — | — | US | disclosed |
| EP-0779277-A1 | 1,4-DIHYDROPYRIDINE DERIVATIVE | MERCIAN CORPORATION (JP) | 1997-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229910-A1 | Therapeutic compounds | BDNF, PNMT, SLC18A2 | ADRA2C 69/4885MAOB 19/4885CLK4 3963/4885 |
| US-20020037885-A1 | Therapeutic compounds | BDNF, PNMT, SLC18A2 | ADRA2C 69/4885MAOB 19/4885CLK4 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.